secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2026-08-04T11:10:14+00:00
Accession:  0001628280-26-052150
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 Therapeutics closes second tranche of $100M private placement, raising $50.1M
--------------------------------------------------------------------------------

- Second closing gross proceeds $50.1M from 10.76M shares at $1.53 and 21.93M pre-funded warrants at $1.5299.
- Total private placement $100M; proceeds to fund CMP-002 Phase 1/2 trial for SYNGAP1-related disorder.
- Investors include Coastlands Capital, Janus Henderson, Balyasny, Vivo Capital, 5AM Ventures, Adage Capital, Trails Edge, CURE SYNGAP1.
- Pre-funded warrants exercisable at $0.0001, subject to 19.99% beneficial ownership limitation.
- Securities issued in private placement not registered under Securities Act.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000162828026052150/0001628280-26-052150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000162828026052150/camp-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-052150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer